Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
20.96
-0.68 (-3.14%)
At close: Feb 27, 2026, 4:00 PM EST
20.80
-0.16 (-0.76%)
After-hours: Feb 27, 2026, 7:55 PM EST
Apellis Pharmaceuticals Revenue
In the year 2025, Apellis Pharmaceuticals had annual revenue of $1.00B with 28.46% growth. Apellis Pharmaceuticals had revenue of $199.91M in the quarter ending December 31, 2025, a decrease of -5.94%.
Revenue (ttm)
$1.00B
Revenue Growth
+28.46%
P/S Ratio
2.67
Revenue / Employee
$1,358,298
Employees
739
Market Cap
2.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00B | 222.42M | 28.46% |
| Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
| Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
| Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
| Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
| Dec 31, 2020 | 250.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
| Liquidia | 69.22M |
| Wave Life Sciences | 42.73M |
APLS News
- 4 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 days ago - Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 9 days ago - Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting - GlobeNewsWire
- 18 days ago - Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - PRNewsWire
- 5 weeks ago - Apellis Valuation Ignores Empaveli Potential, Says Analyst - Benzinga
- 6 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha